Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710001 | 0.90 | HIF1A (0.34) | HIF1ALRRK2 | |
| SCHEMBL6707637 | 0.90 | HIF1A (0.39) | HIF1ACYP1A2 | |
| SCHEMBL6709888 | 0.89 | HIF1A (0.47) | HIF1AROCK1 | |
| SCHEMBL6710321 | 0.88 | MAPT (0.42) | HIF1ALRRK2CYP1A2 | |
| SCHEMBL6708765 | 0.88 | HIF1A (0.43) | HIF1ALRRK2ROCK1 | |
| SCHEMBL6710174 | 0.87 | HIF1A (0.36) | ESR1ESR2HIF1AHSP90AA1LMNA | |
| SCHEMBL6710147 | 0.86 | TP53 (0.34) | HIF1ALRRK2LMNACYP1A2 | |
| SCHEMBL6707842 | 0.86 | HIF1A (0.43) | ESR1ESR2HIF1AHSP90AA1ROCK1 | |
| SCHEMBL6711786 | 0.86 | TNIK (0.38) | HIF1ATNIKLRRK2 | |
| SCHEMBL6709290 | 0.85 | GPR35 (0.34) | HIF1ALRRK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | ESR1 237/4885ESR2 1251/4885HIF1A 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.